Laboratorios Farmaceuticos Rovi (ROVI) Aperçu de l'action
Laboratorios Farmaceuticos Rovi, S.A. fabrique, vend et commercialise des produits pharmaceutiques en Espagne, dans l'Union européenne, dans les pays de l'OCDE et au niveau international. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 4/6 |
| Performances passées | 2/6 |
| Santé financière | 5/6 |
| Dividendes | 3/6 |
Récompenses
Analyse des risques
ROVI Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€51.25
FV
14.7% surévalué décote intrinsèque4.00%
Revenue growth p.a.
138
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Laboratorios Farmaceuticos Rovi, S.A. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €58.80 |
| Plus haut sur 52 semaines | €86.70 |
| Plus bas sur 52 semaines | €51.65 |
| Bêta | 0.22 |
| Variation sur 1 mois | -1.75% |
| Variation sur 3 mois | -25.57% |
| Variation sur 1 an | 5.00% |
| Variation sur 3 ans | 39.14% |
| Variation sur 5 ans | 3.52% |
| Évolution depuis l'introduction en bourse | 488.00% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour du récit • Jun 02
ROVI: Medium Term Contract Risks Will Still Support Future Returns
Analysts have trimmed the fair value estimate for Laboratorios Farmaceuticos Rovi from about €82.48 to €76.49 after recent downgrades flagged softer revenue growth assumptions, slightly lower profit margins and a modestly higher future P/E, with some noting medium term risks linked to Moderna exposure and declining vaccination volumes. Analyst Commentary Recent research has tilted more cautious on Laboratorios Farmaceuticos Rovi, with several downgrades pointing to a reassessment of growth, margins and risk tied to its partner exposure.Article d’analyse • Feb 09
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Feb 03
ROVI: Slightly Higher Fair Value And P/E Will Support Future Returns
Analysts have nudged their price target for Laboratorios Farmaceuticos Rovi slightly higher, with a modest upward revision in fair value tied to refreshed assumptions for revenue, profit margins and future P/E multiples. Valuation Changes Fair Value: Adjusted slightly higher from €81.97 to €82.48 per share, reflecting refreshed model assumptions.Mise à jour du récit • Jan 20
ROVI: Stable Returns And Slightly Higher Multiple Will Support Future Earnings
Analysts have nudged up their fair value estimate for Laboratorios Farmaceuticos Rovi from €80.96 to €81.97, citing slightly higher revenue growth assumptions, a small adjustment in expected profit margins, and a modestly higher future P/E multiple as key drivers of the new target. Valuation Changes Fair Value Estimate was adjusted slightly from €80.96 to €81.97, reflecting a small uplift in the modelled valuation.Mise à jour du récit • Jan 05
ROVI: Stable Returns And Margins Will Support Stronger Future Earnings
Analysts have kept their price target for Laboratorios Farmaceuticos Rovi unchanged, citing stable assumptions around a fair value of €80.96, a discount rate of 7.65%, revenue growth of 12.59%, a profit margin of 23.81% and a future P/E of 20.93 to support their view. Valuation Changes Fair Value: The fair value estimate remains unchanged at €80.96 per share, reflecting the same core valuation outcome as before.Mise à jour du récit • Dec 15
ROVI: Stable Margins And Growth Outlook Will Support Stronger Future Earnings
Analysts have modestly adjusted their price targets for Laboratorios Farmaceuticos Rovi, now valuing the shares around €80.96. They reiterate expectations for solid double digit revenue growth, resilient profit margins, and a stable long term valuation multiple.Mise à jour du récit • Dec 01
ROVI: Increasing Profit Margins Will Drive Stronger Earnings Outlook
Analysts have modestly increased their price target for Laboratorios Farmaceuticos Rovi to €80.96 per share. They cite improving profit margin forecasts as the primary driver of the change.Mise à jour du récit • Nov 17
ROVI: Revenue Acceleration Projected To Drive Upside Despite Margin Pressure
Analysts have raised their price target for Laboratorios Farmaceuticos Rovi from €79.41 to €80.96. They cite improved revenue growth projections, despite slightly lower profit margins and a marginal increase in the discount rate.Article d’analyse • Nov 09
Here's What Analysts Are Forecasting For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) After Its Third-Quarter Results
It's been a mediocre week for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shareholders, with the stock dropping...Article d’analyse • Nov 06
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jun 14
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Dividend Will Be Reduced To €0.7574
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Article d’analyse • May 27
Laboratorios Farmaceuticos Rovi's (BME:ROVI) Shareholders Will Receive A Smaller Dividend Than Last Year
Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) has announced that on 16th of July, it will be paying a dividend...Article d’analyse • Feb 09
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Nouveau récit • Dec 26
Okedi Expansion And Heparin Integration To Boost Revenue And Net Margins
Focus on Okedi and enoxaparin indicates potential revenue growth and improved profit margins from European development and heparin sales volume.Article d’analyse • Nov 10
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
There's been a notable change in appetite for Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) shares in the week...Article d’analyse • Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Article d’analyse • Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €146...Article d’analyse • Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet
Key Insights Laboratorios Farmaceuticos Rovi will host its Annual General Meeting on 24th of June Salary of €743.0k is...Article d’analyse • May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price
When close to half the companies in Spain have price-to-earnings ratios (or "P/E's") below 16x, you may consider...Article d’analyse • Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Laboratorios Farmaceuticos Rovi fair value estimate is €92.64...Article d’analyse • Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Key Insights The projected fair value for Laboratorios Farmaceuticos Rovi is €73.44 based on 2 Stage Free Cash Flow to...Article d’analyse • Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €52.88 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Article d’analyse • May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Key Insights Laboratorios Farmaceuticos Rovi's estimated fair value is €51.68 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
In this article we are going to estimate the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) by...Article d’analyse • Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Laboratorios...Article d’analyse • Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Rendement pour les actionnaires
| ROVI | ES Pharmaceuticals | ES Marché | |
|---|---|---|---|
| 7D | 0% | -0.7% | 0.4% |
| 1Y | 5.0% | 0.6% | 25.9% |
Rendement vs Industrie: ROVI a dépassé le secteur Spanish Pharmaceuticals qui a rapporté 0.6 % au cours de l'année écoulée.
Rendement vs marché: ROVI a sous-performé le marché Spanish qui a rapporté 25.9 % au cours de l'année écoulée.
Volatilité des prix
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 3.4% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in ES Market | 6.6% |
| 10% least volatile stocks in ES Market | 0.9% |
Cours de l'action stable: Le cours de l'action de ROVI a été volatil au cours des 3 derniers mois par rapport au marché Spanish.
Volatilité au fil du temps: La volatilité hebdomadaire de ROVI ( 6% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Spanish.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1946 | 1,998 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. fabrique, vend et commercialise des produits pharmaceutiques en Espagne, dans l'Union européenne, dans les pays de l'OCDE et au niveau international. La société propose des produits de prescription, notamment Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, et Volutsa. Elle fournit également des produits hospitaliers, tels que Iomeron et Iopamiro, Multihance et Y Prohance, Sonovue, Empowercta+, Empowermr et CT Express ; des soins pour cathéters sous la marque Fibrilin ; et l'héparine sodique Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Résumé des fondamentaux
| ROVI statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €2.97b |
| Bénéfices(TTM) | €131.82m |
| Recettes(TTM) | €741.09m |
22.8x
Ratio P/E4.1x
Ratio P/SLe site ROVI est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ROVI compte de résultat (TTM) | |
|---|---|
| Recettes | €741.09m |
| Coût des recettes | €267.01m |
| Marge brute | €474.08m |
| Autres dépenses | €342.26m |
| Les revenus | €131.82m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 23, 2026
| Résultat par action (EPS) | 2.58 |
| Marge brute | 63.97% |
| Marge bénéficiaire nette | 17.79% |
| Ratio dettes/capitaux propres | 14.6% |
Quelles ont été les performances à long terme de ROVI?
Voir les performances historiques et les comparaisonsDividendes
1.6%
Rendement actuel des dividendes35%
Ratio de distributionLe site ROVI verse-t-il des dividendes fiables ?
Voir ROVI l'historique des dividendes et les indices de référence| Laboratorios Farmaceuticos Rovi dates des dividendes | |
|---|---|
| Date ex-dividende | Jul 13 2026 |
| Date de paiement du dividende | Jul 15 2026 |
| Jours jusqu'au dividende Ex | 30 days |
| Jours jusqu'à la date de paiement du dividende | 32 days |
Le site ROVI verse-t-il des dividendes fiables ?
Voir ROVI l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/12 19:20 |
| Cours de l'action en fin de journée | 2026/06/12 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Laboratorios Farmaceuticos Rovi, S.A. est couverte par 13 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |